(Q34201654)

31 July 2017

title

Neuropsychological change in schizophrenia after 6 weeks of clozapine (English)

1 reference

31 July 2017

0 references

1 reference

S E Purdon

1

1 reference

31 July 2017

A Labelle

series ordinal

2

1 reference

31 July 2017

L Boulay

series ordinal

3

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 March 2001

1 reference

31 July 2017

published in

Schizophrenia Research

1 reference

31 July 2017

volume

48

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

57-67

1 reference

Neurocognitive impairment in schizophrenia and how it affects treatment options

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Neuropsychological impairments in deficit vs nondeficit forms of schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Does risperidone improve verbal working memory in treatment-resistant schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Schizophrenia with good and poor outcome. III: Neurological 'soft' signs, cognitive impairment and their clinical significance.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

The effects of neuroleptics on neuropsychological test results of schizophrenics.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Neuropsychologic deficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Neuropsychological discriminators of long-term inpatient or outpatient status in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Cognitive improvement in schizophrenia with novel antipsychotic medications

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Asymmetrical olfactory acuity and neuroleptic treatment in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Cognitive and motor impairments are related to gray matter volume deficits in schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Neuroleptic effects on interhemispheric and intrahemispheric performance of tactile discrimination tasks by schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Neuroleptics reverse attention asymmetries in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2800%2900101-8

7 January 2021

10.1016/S0920-9964(00)00101-8

Identifiers

DOI

1 reference

31 July 2017

1 reference